Browsing by Author Gogas, H.

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Jump to: Α Β Γ Δ Ε Ζ Η Θ Ι Κ Λ Μ Ν Ξ Ο Π Ρ Σ Τ Υ Φ Χ Ψ Ω
or enter first few letters:  
View Option
Showing results 1 to 20 of 26  next >
TitleAuthor(s)Issue date???itemlist.???
Combination chemotherapy with paclitaxel and gemcitabine followed by concurrent chemoradiotherapy in non-operable localized non-small cell lung cancer. A hellenic cooperative oncology group (HeCOG) phase II studyKosmidis, P.; Fountzilas, G.; Baka, S.; Samantas, E.; Dimopoulos, A. M.; Gogas, H.; Skarlos, D.; Papacostas, P.; Boukovinas, J.; Bakogiannis, C.; Pantelakos, P.; Athanasiou, H.; Misailidou, D.; Tsekeris, P.; Pavlidis, N.24-Nov-2015-
Docetaxel and gemcitabine combination, as first-line treatment, in patients with extensive disease small-cell lung cancer. A phase II study of the Hellenic Cooperative Oncology GroupSkarlos, D. V.; Dimopoulos, A. M.; Kosmidis, P.; Papakostas, P.; Pavlidis, N.; Bacoyiannis, C.; Kiamouris, C.; Klouvas, G.; Gogas, H.; Fountzilas, G.; Samantas, E.24-Nov-2015-
Docetaxel in combination with dacarbazine in patients with advanced melanomaBafaloukos, D.; Aravantinos, G.; Fountzilas, G.; Stathopoulos, G.; Gogas, H.; Samonis, G.; Briasoulis, E.; Mylonakis, N.; Skarlos, D. V.; Kosmidis, P.24-Nov-2015-
Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) studyKoutras, A. K.; Kalogeras, K. T.; Dimopoulos, M. A.; Wirtz, R. M.; Dafni, U.; Briasoulis, E.; Pectasides, D.; Gogas, H.; Christodoulou, C.; Aravantinos, G.; Zografos, G.; Timotheadou, E.; Papakostas, P.; Linardou, H.; Razis, E.; Economopoulos, T.; Kalofonos, H. P.; Fountzilas, G.24-Nov-2015-
Evaluation of the prognostic and predictive value of HER-1/EGFR in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapyTzaida, O.; Gogas, H.; Dafni, U.; Kyroudi, A.; Papaspyrou, I.; Kyriakou, V.; Malamou-Mitsi, V.; Alamani, M.; Skopa, C.; Kostopoulos, I.; Kastritis, E.; Pectasides, D.; Briasoulis, E.; Kalofonos, H. P.; Aravantinos, G.; Fountzilas, G.; Arapantoni-Dadioti, P.24-Nov-2015-
Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapyMalamou-Mitsi, V.; Gogas, H.; Dafni, U.; Bourli, A.; Fillipidis, T.; Sotiropoulou, M.; Vlachodimitropoulos, D.; Papadopoulos, S.; Tzaida, O.; Kafiri, G.; Kyriakou, V.; Markaki, S.; Papaspyrou, I.; Karagianni, E.; Pavlakis, K.; Toliou, T.; Scopa, C.; Papakostas, P.; Bafaloukos, D.; Christodoulou, C.; Fountzilas, G.24-Nov-2015-
Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapyKostopoulos, I.; Arapantoni-Dadioti, P.; Gogas, H.; Papadopoulos, S.; Malamou-Mitsi, V.; Scopa, C. D.; Markaki, S.; Karagianni, E.; Kyriakou, V.; Margariti, A.; Kyrkou, E.; Pavlakis, K.; Zaramboukas, T.; Skordalaki, A.; Bourli, A.; Markopoulos, C.; Pectasides, D.; Dimopoulos, M. A.; Skarlos, D.; Fountzilas, G.24-Nov-2015-
Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II studySkarlos, D. V.; Kalofonos, H. P.; Fountzilas, G.; Dimopoulos, M. A.; Pavlidis, N.; Razis, E.; Economopoulos, T.; Pectasides, D.; Gogas, H.; Kosmidis, P.; Bafaloukos, D.; Klouvas, G.; Kyratzis, G.; Aravantinos, G.24-Nov-2015-
Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trialPentheroudakis, G.; Kalogeras, K. T.; Wirtz, R. M.; Grimani, I.; Zografos, G.; Gogas, H.; Stropp, U.; Pectasides, D.; Skarlos, D.; Hennig, G.; Samantas, E.; Bafaloukos, D.; Papakostas, P.; Kalofonos, H. P.; Pavlidis, N.; Fountzilas, G.24-Nov-2015-
HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapyFountzilas, G.; Valavanis, C.; Kotoula, V.; Eleftheraki, A. G.; Kalogeras, K. T.; Tzaida, O.; Batistatou, A.; Kronenwett, R.; Wirtz, R. M.; Bobos, M.; Timotheadou, E.; Soupos, N.; Pentheroudakis, G.; Gogas, H.; Vlachodimitropoulos, D.; Polychronidou, G.; Aravantinos, G.; Koutras, A.; Christodoulou, C.; Pectasides, D.; Arapantoni, P.24-Nov-2015-
Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 womenPentheroudakis, G.; Fountzilas, G.; Bafaloukos, D.; Koutsoukou, V.; Pectasides, D.; Skarlos, D.; Samantas, E.; Kalofonos, H. P.; Gogas, H.; Pavlidis, N.24-Nov-2015-
Myelotoxicity as a prognostic factor in patients with advanced breast cancer treated with chemotherapy: a pooled analysis of two randomised trials conducted by the Hellenic Cooperative Oncology GroupKoutras, A. K.; Fountzilas, G.; Dafni, U.; Dimopoulos, M. A.; Pectasides, D.; Klouvas, G.; Papakostas, P.; Kosmidis, P.; Samantas, E.; Gogas, H.; Briasoulis, E.; Vourli, G.; Petsas, T.; Xiros, N.; Kalofonos, H. P.24-Nov-2015-
Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology GroupFountzilas, G.; Pectasides, D.; Kalogera-Fountzila, A.; Skarlos, D.; Kalofonos, H. P.; Papadimitriou, C.; Bafaloukos, D.; Lambropoulos, S.; Papadopoulos, S.; Kourea, H.; Markopoulos, C.; Linardou, H.; Mavroudis, D.; Briasoulis, E.; Pavlidis, N.; Razis, E.; Kosmidis, P.; Gogas, H.24-Nov-2015-
Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology GroupFountzilas, G.; Kalofonos, H. P.; Dafni, U.; Papadimitriou, C.; Bafaloukos, D.; Papakostas, P.; Kalogera-Fountzila, A.; Gogas, H.; Aravantinos, G.; Moulopoulos, L. A.; Economopoulos, T.; Pectasides, D.; Maniadakis, N.; Siafaka, V.; Briasoulis, E.; Christodoulou, C.; Tsavdaridis, D.; Makrantonakis, P.; Razis, E.; Kosmidis, P.; Skarlos, D.; Dimopoulos, M. A.24-Nov-2015-
Phase II study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancerAravantinos, G.; Bafaloukos, D.; Fountzilas, G.; Christodoulou, C.; Papadimitriou, C.; Pavlidis, N.; Kalofonos, H. P.; Gogas, H.; Kosmidis, P.; Dimopoulos, M. A.24-Nov-2015-
Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology GroupFountzilas, G.; Skarlos, D.; Dafni, U.; Gogas, H.; Briasoulis, E.; Pectasides, D.; Papadimitriou, C.; Markopoulos, C.; Polychronis, A.; Kalofonos, H. P.; Siafaka, V.; Kosmidis, P.; Timotheadou, E.; Tsavdaridis, D.; Bafaloukos, D.; Papakostas, P.; Razis, E.; Makrantonakis, P.; Aravantinos, G.; Christodoulou, C.; Dimopoulos, A. M.24-Nov-2015-
Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00Fountzilas, G.; Dafni, U.; Gogas, H.; Linardou, H.; Kalofonos, H. P.; Briasoulis, E.; Pectasides, D.; Samantas, E.; Bafaloukos, D.; Stathopoulos, G. P.; Karina, M.; Papadimitriou, C.; Skarlos, D.; Pisanidis, N.; Papakostas, P.; Markopoulos, C.; Tzorakoeleftherakis, E.; Dimitrakakis, K.; Makrantonakis, P.; Xiros, N.; Polichronis, A.; Varthalitis, I.; Karanikiotis, C.; Dimopoulos, A. M.24-Nov-2015-
Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III TrialGogas, H.; Dafni, U.; Karina, M.; Papadimitriou, C.; Batistatou, A.; Bobos, M.; Kalofonos, H. P.; Eleftheraki, A. G.; Timotheadou, E.; Bafaloukos, D.; Christodoulou, C.; Markopoulos, C.; Briasoulis, E.; Papakostas, P.; Samantas, E.; Kosmidis, P.; Stathopoulos, G. P.; Karanikiotis, C.; Pectasides, D.; Dimopoulos, M. A.; Fountzilas, G.24-Nov-2015-
Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group StudyFostira, F.; Tsitlaidou, M.; Papadimitriou, C.; Pertesi, M.; Timotheadou, E.; Stavropoulou, A. V.; Glentis, S.; Bournakis, E.; Bobos, M.; Pectasides, D.; Papakostas, P.; Pentheroudakis, G.; Gogas, H.; Skarlos, P.; Samantas, E.; Bafaloukos, D.; Kosmidis, P. A.; Koutras, A.; Yannoukakos, D.; Konstantopoulou, I.; Fountzilas, G.24-Nov-2015-
Prognostic significance of UBE2C mRNA expression in high-risk early breast cancer. A Hellenic Cooperative Oncology Group (HeCOG) StudyPsyrri, A.; Kalogeras, K. T.; Kronenwett, R.; Wirtz, R. M.; Batistatou, A.; Bournakis, E.; Timotheadou, E.; Gogas, H.; Aravantinos, G.; Christodoulou, C.; Makatsoris, T.; Linardou, H.; Pectasides, D.; Pavlidis, N.; Economopoulos, T.; Fountzilas, G.24-Nov-2015-